Stockscreener 앱 받기
6.27
0.64%
0.04
시간 외 거래:
6.27
Organon Co 주식(OGN)의 최신 뉴스
Organon & Co. Hits New 52-Week Low at USD 6.16 Amidst Declining Performance - Markets Mojo
Organon & Co stock hits 52-week low at 6.17 USD By Investing.com - Investing.com South Africa
Organon & Co stock hits 52-week low at 6.17 USD - Investing.com Australia
Organon (OGN) Falls More Steeply Than Broader Market: What Investors Need to Know - Yahoo Finance Singapore
Organon leads ultra-low P/E stocks at 1.8x as small-cap stocks face volatility (IJR:NYSEARCA) - Seeking Alpha
Organon & Co. (NYSE:OGN) Hits New 12-Month LowHere's Why - MarketBeat
Organon rises after update on independent review - MSN
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates - GuruFocus
Investors heavily search Organon & Co. (OGN): Here is what you need to know - MSN
Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know - Yahoo! Finance Canada
Aug Wrap: Can Organon Co expand into new marketsWeekly Trade Recap & Reliable Volume Spike Alerts - baoquankhu1.vn
Organon & Co. Experiences Evaluation Revision Amidst Market Challenges and Performance Divergence - Markets Mojo
Gotham Asset Management LLC Buys 1,007,691 Shares of Organon & Co. $OGN - MarketBeat
Organon (OGN) Stock Analysis Report | Ratings, Financials & Performance - Benzinga Japan
Organon & Co. (OGN) Dividend Yield 2026, Date & History $OGN - MarketBeat
OGN Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Organon Q4 2025 slides: Revenue declines accelerate, stock tumbles on earnings miss - Investing.com Nigeria
Organon trades in red for seven straight sessions - MSN
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Organon & Co. (OGN) And Encourages Shareholders to Reach Out - ACCESS Newswire
(OGN) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Organon Q3 Net Margin Squeeze Challenges Bullish Earnings Growth Narratives - Sahm
Organon outlines flat $6.2B revenue and $1.9B EBITDA targets for 2026 as cost controls and portfolio shifts take center stage - MSN
Royce & Associates LP Trims Position in Organon & Co. $OGN - MarketBeat
Organon climbs 6% after audit clears company of wrongdoing - MSN
Organon & Co. (OGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Organon & Co. Hits Day Low of $7.50 Amid Price Pressure - Markets Mojo
Bronstein, Gewirtz & Grossman, LLC Encourages Organon & Co. (OGN) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Organon (OGN) HR chief gets stock awards, withholds shares for taxes - Stock Titan
Organon & Co. (NYSE:OGN) Short Interest Up 21.9% in February - MarketBeat
Organon (OGN) CFO granted shares, withholds stock to pay taxes - Stock Titan
Organon (OGN) executive reports PSU share awards and tax withholding - Stock Titan
Organon (OGN) CIO logs stock awards and tax withholding share disposals - Stock Titan
Organon (OGN) GC Weaver gets stock awards, shares withheld for tax - Stock Titan
Organon (NYSE: OGN) interim CEO reports stock awards and tax share offsets - Stock Titan
Can VTAMA’s Pediatric Sleep Data Nudge Organon (OGN) Toward a Stronger Dermatology-Led Growth Identity? - simplywall.st
Organon & Co. (OGN) Stock Analysis: Key Insights On Its 25.17% Potential Upside - DirectorsTalk Interviews
KDventures AB Announces Organon Discontinues Development of Forendo's Drug Candidate for Polycystic Ovarian Syndrome - marketscreener.com
KDventures meddelar att Organon har avbrutit utvecklingen av det tidigare portföljbolaget Forendos läkemedelskandidat mot PCOS - GlobeNewswire Inc.
Organon & Co. (NYSE:OGN) Receives Average Rating of "Reduce" from Brokerages - MarketBeat
OGN's VTAMA Cream Shows Sleep Benefits in Pediatric Atopic Dermatitis - Bitget
Organon & Co. (OGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Is Organon (OGN) Pricing Reflect Its Value After Reported Sun Pharma Takeover Interest - Yahoo Finance
OGN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Organon presents sleep improvement data for VTAMA cream in children By Investing.com - Investing.com Australia
Assessing Organon (OGN) Valuation After VTAMA Sleep Outcome Data From Phase 3 ADORING Trials - simplywall.st
Organon presents sleep improvement data for VTAMA cream in children - Investing.com
Vanguard Group Inc. Has $383.72 Million Position in Organon & Co. $OGN - MarketBeat
New Analysis of Organon’s VTAMA® (tapinarof) cream, 1%, Phase 3 Data Showed Early and Consistent Improvement in Patient-Reported Sleep Subdomains in Pediatric Patients Down to 2 Years of Age with Atopic Dermatitis - Business Wire
Organon Refocuses On Contraception With MIUDELLA Deal And JADA Exit - simplywall.st
Organon & Co. Confronts Mounting Global Pricing Pressure as Health Reforms Threaten Margin Stability and Nexplanon Growth - TipRanks
Organon & Co. (NYSE:OGN) Trading Down 6.3%Time to Sell? - MarketBeat
Organon & Co. (OGN) Stock Analysis: Navigating a Potential Upside Amidst a Challenging Landscape - DirectorsTalk Interviews
Decoding Organon & Co (OGN): A Strategic SWOT Insight - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Encourages Organon & Co. (OGN) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Organon & Co. (NYSE:OGN) Price Target Raised to $8.00 at Barclays - MarketBeat
Organon price target raised to $8 from $7.50 at Barclays - TipRanks
Organon licenses hormone-free copper IUD from Sebela Pharmaceuticals By Investing.com - Investing.com India
Organon & Co. (OGN) posts FY adjusted EPS of $3.66, EBITDA margin at 30.7% - MSN
Organon & Co. (OGN) Posts FY Adjusted EPS of $3.66, EBITDA Margin at 30.7% - Insider Monkey
0.33%
0.99%
자본화:
|
볼륨(24시간):